Jupiter Neurosciences shares are rising Wednesday after it announced the acquisition of US licensing rights to ALA-002 from Pharmala Biotech.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.
Jupiter stock is showing upward momentum. What’s next for JUNS stock?
J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)
Neurocrine Biosciences Hits New Highs On Earnings Surge
J.P. Morgan Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)
J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Bluejay Diagnostics partners with Argonaut to scale U.S. manufacturing and distribution for its Symphony critical care platform.…
Shares of J&J rose about 1% Tuesday, shaking off their premarket declines.
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on AnaptysBio, with a price target of…
Morgan Stanley's price target implies that shares of Johnson & Johnson could rise another 17%.
Biotech stock Neurocrine Biosciences is hovering below its all-time high after first-quarter earnings surged more than 2,000%.
